968 related articles for article (PubMed ID: 28520872)
1. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
[TBL] [Abstract][Full Text] [Related]
2. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
3. The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice.
Migdalska-Richards A; Wegrzynowicz M; Rusconi R; Deangeli G; Di Monte DA; Spillantini MG; Schapira AHV
Brain; 2017 Oct; 140(10):2706-2721. PubMed ID: 28969384
[TBL] [Abstract][Full Text] [Related]
4. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
[TBL] [Abstract][Full Text] [Related]
5. Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.
Rockenstein E; Clarke J; Viel C; Panarello N; Treleaven CM; Kim C; Spencer B; Adame A; Park H; Dodge JC; Cheng SH; Shihabuddin LS; Masliah E; Sardi SP
Hum Mol Genet; 2016 Jul; 25(13):2645-2660. PubMed ID: 27126635
[TBL] [Abstract][Full Text] [Related]
6. Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques.
Sucunza D; Rico AJ; Roda E; Collantes M; González-Aseguinolaza G; Rodríguez-Pérez AI; Peñuelas I; Vázquez A; Labandeira-García JL; Broccoli V; Lanciego JL
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062940
[TBL] [Abstract][Full Text] [Related]
7. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death.
Keatinge M; Bui H; Menke A; Chen YC; Sokol AM; Bai Q; Ellett F; Da Costa M; Burke D; Gegg M; Trollope L; Payne T; McTighe A; Mortiboys H; de Jager S; Nuthall H; Kuo MS; Fleming A; Schapira AH; Renshaw SA; Highley JR; Chacinska A; Panula P; Burton EA; O'Neill MJ; Bandmann O
Hum Mol Genet; 2015 Dec; 24(23):6640-52. PubMed ID: 26376862
[TBL] [Abstract][Full Text] [Related]
9. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
[TBL] [Abstract][Full Text] [Related]
10. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
Yang SY; Gegg M; Chau D; Schapira A
Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
[TBL] [Abstract][Full Text] [Related]
12. Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.
Davis MY; Trinh K; Thomas RE; Yu S; Germanos AA; Whitley BN; Sardi SP; Montine TJ; Pallanck LJ
PLoS Genet; 2016 Mar; 12(3):e1005944. PubMed ID: 27019408
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.
Gordon R; Singh N; Lawana V; Ghosh A; Harischandra DS; Jin H; Hogan C; Sarkar S; Rokad D; Panicker N; Anantharam V; Kanthasamy AG; Kanthasamy A
Neurobiol Dis; 2016 Sep; 93():96-114. PubMed ID: 27151770
[TBL] [Abstract][Full Text] [Related]
14. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
15. Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.
Sardi SP; Singh P; Cheng SH; Shihabuddin LS; Schlossmacher MG
Neurodegener Dis; 2012; 10(1-4):195-202. PubMed ID: 22327140
[TBL] [Abstract][Full Text] [Related]
16. GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice.
Gregorio I; Russo L; Torretta E; Barbacini P; Contarini G; Pacinelli G; Bizzotto D; Moriggi M; Braghetta P; Papaleo F; Gelfi C; Moro E; Cescon M
Mol Neurodegener; 2024 Mar; 19(1):22. PubMed ID: 38454456
[TBL] [Abstract][Full Text] [Related]
17. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
[TBL] [Abstract][Full Text] [Related]
18. A double-hit in vivo model of GBA viral microRNA-mediated downregulation and human alpha-synuclein overexpression demonstrates nigrostriatal degeneration.
Polissidis A; Koronaiou E; Nikolopoulou G; Viel C; Nikatou M; Bogiongko M; Sardi SP; Xilouri M; Vekrellis K; Stefanis L
Neurobiol Dis; 2022 Feb; 163():105612. PubMed ID: 34995756
[TBL] [Abstract][Full Text] [Related]
19. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
20. The relationship between glucocerebrosidase mutations and Parkinson disease.
Migdalska-Richards A; Schapira AH
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]